US-based medical device company QT Imaging Holdings Inc (OTCQB: QTIH) revealed on Monday that it has entered into an exclusive distribution agreement with Gulf Medical Co for the supply of its FDA-cleared Breast Acoustic CT scanner and subscriptions to the QTI Cloud Platform in Saudi Arabia.
The agreement sets minimum orders of five scanners per quarter beginning in the first quarter of 2026 through to the end of 2028, totalling at least 60 scanners and generating revenue of more than USD33m. Gulf Medical will also distribute QTI's AI-enabled cloud platform, designed to enhance breast health imaging through automated classification and second-read decision support.
QTI's non-invasive 3D breast imaging technology, which avoids compression, contrast agents and radiation, is particularly relevant in Saudi Arabia where genetic predispositions, including BRCA1 and BRCA2 mutations, contribute to higher breast cancer incidence among women aged 40 to 59.
Founded in 1983, Gulf Medical Co, part of the Al-Naghi Group, is a leading distributor of medical technologies across the Middle East.
QT Imaging Holdings is a US-based medical device company focused on safe, affordable and patient-centered imaging systems using low-frequency sound waves.
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Medtronic seeks expanded US approvals for Hugo robotic surgery system
Waters secures FDA clearance for BD BACTEC FXI Blood Culture System
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
ILC Dover adds Water for Injection (WFI) and custom chemical solutions to offerings
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Implantica submits final FDA response for RefluxStop PMA application
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AngioDynamics reports 24-month PRESERVE data showing durable NanoKnife outcomes in prostate cancer